Person:
KARADAĞ, BÜLENT TANER

Loading...
Profile Picture

Email Address

Birth Date

Research Projects

Organizational Units

Organizational Unit

Job Title

Last Name

KARADAĞ

First Name

BÜLENT TANER

Name

Search Results

Now showing 1 - 10 of 42
  • Publication
    Bronchoscopic evaluation of unexplained recurrent and persistent pneumonia in children
    (WILEY-BLACKWELL, 2013) KARADAĞ, BÜLENT TANER; Gokdemir, Yasemin; Cakir, Erkan; Kut, Arif; Erdem, Ela; Karadag, Bulent; Ersu, Refika; Karakoc, Fazilet
    d Background: Persistent or recurrent pneumonia in children can pose a significant challenge to paediatricians and respiratory physicians. Aim: The aim of this study is to determine the role of flexible bronchoscopy (FB) in evaluation of recurrent or persistent pneumonia that remain otherwise unexplained by non-invasive diagnostic tests in children. Methods: Retrospective evaluation of patients who underwent FB with an indication of recurrent or persistent pneumonia from 1997 to 2011. Results: Among 2600 FB procedures, 434 (17%) were performed with the indication of recurrent or persistent pneumonia. There were 237 (54%) boys. Median age at presentation was 84 months, and median duration of symptoms was 9 months. FB led to specific diagnosis in 33% of the cases. The most common diseases diagnosed by FB were malacia disorders (n: 32, 7%), aspirated foreign body (n: 30, 7%), endobronchial tuberculosis (n: 20, 5%), congenital airway anomalies (n: 14, 3%), mucus plugs (n: 14, 3%), pulmonary haemosiderosis (n: 12, 3%) and middle lobe syndrome (n: 11, 3%). During FB, only 6% of the patients had minor complications such as transient hypoxia, stridor and tachycardia. Conclusions: In our study, FB proved to be a safe and effective tool in evaluation of children with persistent or recurrent pneumonia. FB is indicated for children with recurrent or persistent pneumonia where the underlying diagnosis remains unclear even after non-invasive diagnostic tests.
  • Publication
    Reliability and validity of the Cystic Fibrosis Questionnaire-Revised for children and parents in Turkey: cross-sectional study
    (SPRINGER, 2013) KARADAĞ, BÜLENT TANER; Yuksel, Hasan; Yilmaz, Ozge; Dogru, Deniz; Karadag, Bulent; Unal, Fatih; Quittner, Alexandra L.
    The purpose of study was to translate Cystic Fibrosis Questionnaire-Revised (CFQ-R) into Turkish for children with cystic fibrosis (CF) and evaluate its reliability and validity. This is the first CF-specific health-related quality of life (HRQOL) measure validated in a Muslim country. Fifty-one children aged 6-13 years treated at four centers in Turkey and 30 parents participated in this cross-sectional study. Demographic characteristics and disease severity parameters were recorded for all participants. All participants completed the parent or child versions of CFQ-R and KINDL questionnaires at enrollment. Reliability and construct validity analysis were carried out. Both children and parents endorsed a range of responses, with no evidence of floor or ceiling effects. Item-to-total correlations indicated that most items were more highly correlated with their intended scale than competing scales. Good internal consistency was found for majority of child and parent scales. CFQ-R scales correlated significantly with clinical indices of disease severity. Good evidence of convergent validity with a generic HRQOL scale was found. Turkish versions of CFQ-R Child and Parent instruments have demonstrated adequate reliability and validity and can be utilized in clinical trials or integrated into clinical evaluation and follow-up of Turkish children with CF.
  • PublicationOpen Access
    Key paediatric messages from the 2018 European Respiratory Society International Congress
    (EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2019-04) KARADAĞ, BÜLENT TANER; Nenna, Raffaella; Hunt, Katie A.; Dassios, Theodore; Collins, Jennifer J. P.; Rottier, Robbert J.; Liu, Norrice M.; Rottier, Bart; Goutaki, Myrofora; Karadag, Bulent; Prayle, Andrew; Fernandes, Ricardo M.; Parisi, Giuseppe Fabio; Barben, Jurg; Rubbo, Bruna; Snijders, Deborah; Makrinioti, Heidi; Hall, Graham; Pijnenburg, Marielle W.; Grigg, Jonathan
    In this article, the Group Chairs and early career members of the European Respiratory Society (ERS) Paediatric Assembly highlight some of the most interesting findings in the field of paediatrics which were presented at the 2018 international ERS Congress.
  • PublicationOpen Access
    Severe Paediatric Asthma Collaborative in Europe (SPACE): protocol for a European registry
    (EUROPEAN RESPIRATORY SOC JOURNALS LTD, 2018-06) KARADAĞ, BÜLENT TANER; Liu, Norrice M.; van Aalderen, Wim; Carlsen, Karin C. L.; Coleman, Courtney; Chalmers, James D.; Cunningham, Steve; Fernandes, Ricardo M.; Fleming, Louise J.; Gappa, Monika; Karadag, Bulent; Midulla, Fabio; Pijnenburg, Marielle W. H.; Rutjes, Niels W.; Rusconi, Franca; Grigg, Jonathan
    The development of new asthma biologics and receptor blockers for the treatment of paediatric severe asthma raises challenges. It is unclear whether there are sufficient children in Europe to recruit into randomised placebo-controlled trials to establish efficacy and safety in this age group. In February 2016, the European Respiratory Society funded a clinical research collaboration entitled Severe Paediatric Asthma Collaborative in Europe (SPACE). We now report the SPACE protocol for a prospective pan-European observational study of paediatric severe asthma. Inclusion criteria are: 1) age 6-17 years, 2) severe asthma managed at a specialised centre for >= 6 months, 3) clinical and spirometry evidence of asthma, and 4) reaching a pre-defined treatment threshold. The exclusion criterion is the presence of conditions which mimic asthma symptoms. Eligible children will be prospectively recruited into a registry, recording demographics, comorbidities, quality of life, family history, neonatal history, smoking history, asthma background, investigations, and treatment. Follow-up will provide longitudinal data on asthma control and treatment changes. The SPACE registry, by identifying well-phenotyped children eligible for clinical trials, and the amount of overlap in eligibility criteria, will inform the design of European trials in paediatric severe asthma, and facilitate observational research where data from single centres are limited.
  • Publication
    Comparing the Smoking Status of Working Adolescents with Adolescents Enrolled in High School in Turkey
    (MARY ANN LIEBERT INC, 2013) KARADAĞ, BÜLENT TANER; Cakir, Erkan; Karakoc, Fazilet; Ersu, Refika; Karadag, Bulent; Varol, Nezih; Dagli, Elif
    Smoking is one of the most important public health problems. There is limited data about the smoking status of working adolescents. In this study we aimed to compare the smoking status of working adolescents with adolescents enrolled in high school in Turkey. Workers were recruited from a vocational training center, and control subjects were from a local high school. Questionnaires about socioeconomic status and smoking were applied. Eight hundred and two participants (436 workers) were included in the study. The mean age of the participants was 16.8 years. Smoking frequencies were 40% and 21% for the workers' group and the control group, respectively (P < 0.001). Adolescent workers were more frequently exposed to second-hand smoke at home. Working [odds ratio (OR): 2.49, 95% confidence interval (CI): 1.81-3.43], age over 17 (OR: 1.77, 95% CI: 1.28-2.44), and male sex (OR: 1.57, 95% CI: 1.00-2.44) were found to be significantly effective on smoking in the logistic regression analysis. Working adolescents had significantly higher smoking rates and exposed to second-hand smoke at home than high school students. Further studies are needed to explore the reasons of higher smoking rates in working adolescents than in high school students.
  • Publication
    Are home sleep studies useful in diagnosing obstructive sleep apnea in children with down syndrome?
    (WILEY, 2019) KARADAĞ, BÜLENT TANER; Ikizoglu, Nilay Bas; Kiyan, Esen; Polat, Beldan; Ay, Pinar; Karadag, Bulent; Ersu, Refika
    Introduction and Aim Obstructive sleep apnea syndrome (OSAS) is frequent in children with Down syndrome (DS) and polysomnography (PSG) is recommended for all children with DS. However PSG is not always available and alternative diagnostic methods are needed. The aim of the study was to evaluate the feasibility and validity of home polygraphy (HPG) in children with DS. Methods A national DS association was contacted and children aged 6 to 18 years who accepted to participate were recruited. Otorhinolaryngologic evaluation, in-lab PSG and HPG were performed. OSAS was diagnosed by PSG with an apnea-hypopnea index (AHI) more than or equal to 1. OSAS severity was classified as moderate-to-severe if AHI was more than or equal to 5. Receiver operating characteristic curves were calculated for HPG using PSG as the gold standard. Results Nineteen children (12 girls) completed the study. Median age was 11.3 years. Demographic and clinical characteristics were similar in children with and without OSAS. Eighty-nine percent of HPG studies were technically acceptable at the initial night and the success rate was 100% when two failed studies were repeated. PSG revealed OSAS in six (32%) children, two had mild and four had moderate-to-severe OSAS. All four patients with moderate-to-severe OSAS diagnosed with PSG have been diagnosed with the same severity on HPG. HPG had 100% sensitivity and 83% specificity when AHI >= 3 was set as diagnostic criteria. Conclusion HPG is a feasible and reliable test of OSAS in children with DS and may be useful in diagnosis and treatment of patients with moderate-to-severe OSAS in this patient group.
  • Publication
    Oral health in home ventilated children: A pilot study
    (2016-04-17) KARADAĞ, BÜLENT TANER; ŞEN YAVUZ, BETÜL; KARGÜL, BETÜL; BAŞ İKİZOĞLU N., GÜNYÜZ E., KARADAĞ B. T., ÖZBAY G., KULAN P., ŞEN B., KARGÜL B.
  • Publication
    Ev ventilatörlü hastaların ağız ve diş sağlığının değerlendirilmesi pilot çalışma
    (2016-04-14) KARADAĞ, BÜLENT TANER; GÖKDEMİR, YASEMİN; ŞEN YAVUZ, BETÜL; KARGÜL, BETÜL; GÜNYÜZ E., BAŞ İKİZOĞLU N., ŞEN B., GÖKDEMİR Y., KARADAĞ B. T., ÖZBAY G., KULAN P., KARGÜL B.
  • Publication
    Polisomnografi aracılığıyla tanı alan bir nöroblastom olgusu
    (2019-10-11) ERGENEKON, ALMALA PINAR; ERDEM ERALP, ELA; GÖKDEMİR, YASEMİN; EKER, NURŞAH; TOKUÇ, AYŞE GÜLNUR; KARADAĞ, BÜLENT TANER; YILMAZ YEĞİT C., ERGENEKON A. P., ERDEM ERALP E., GÖKDEMİR Y., EKER N., TOKUÇ A. G., KARADAĞ B. T.
  • Publication
    Effect of inhaled steroids on clinical and inflammatory parameters in children with cystic fibrosis
    (TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY, 2017) KARADAĞ, BÜLENT TANER; Uyan, Zeynep Seda; Unluguzel Ustun, Goksenin; Haklar, Goncagul; Cakir, Erkan; Oktem, Sedat; Ersu, Refika; Karadag, Bulent Taner; Karakoc, Fazilet; Dagli, Elif
    Background/aim: The effectiveness of inhaled corticosteroids (ICSs) in cystic fibrosis (CF) is controversial. The aim of this study was to investigate the effect of an ICS on bronchial hyperreactivity (BHR), oxidative status, and clinical and inflammatory parameters in CF patients. Materials and methods: CF patients were randomized to receive either 2 mg/day nebulized budesonide or 0.9% normal saline as placebo for 8 weeks. Results: Twenty-nine CF patients (mean age: 10.5 +/- 2.9 years) were enrolled in the study. There was no statistically significant difference between the two groups at the end of 8 weeks in terms of symptoms, pulmonary function, BHR, oxidative burst, hs-CRP, or ESR. Although there was a significant decrease in malondialdehyde levels in both groups, there was no difference between the two groups. Percentage of neutrophils in the sputum of patients decreased in the budesonide group (P = 0.006). Although sputum IL-8 levels significantly increased in both groups, there was no statistically significant difference between the two groups. Conclusion: Although there was a significant decrease in the percentage of neutrophils in sputum with budesonide, 8 weeks of 2 mg/day nebulized budesonide was not effective in terms of BHR, oxidative status, or clinical and other inflammatory parameters in children with CF.